com_NN Sales_NNS and_CC marketing_NN Key_NNP products_NNS Key_NNP products_NNS :_: Cardiovascular_NNP 1_CD Atacand_NNP candesartan_NN cilexetil_NN angiotensin_NN II_NNP antagonist_NN for_IN hypertension_NN 2_CD Crestor_NNP rosuvastatin_NN calcium_NN HMG-CoA_NNP reductase_NN inhibitor_NN statin_NN for_IN dyslipidemia_NN Exanta_NNP ximelagatran_JJ oral_JJ direct_JJ thrombin_NN inhibitor_NN for_IN prevention_NN of_IN thrombosis_NN in_IN association_NN with_IN major_JJ orthopaedic_JJ surgery_NN Plendil_NNP felodipine_NN calcium_NN antagonist_NN for_IN hypertension_NN and_CC angina_NN Seloken_NNP Toprol-XL_NNP metoprolol_NN succinate_NN beta_JJ blocker_NN for_IN hypertension_NN ,_, angina_NN ,_, heart_NN failure_NN and_CC other_JJ uses_NNS 3_CD Zestril_NNP lisinopril_NN dihydrate_NN angiotensin_NN We_PRP aim_VBP to_TO build_VB on_IN our_PRP$ success_NN In_IN the_DT US_NNP ,_, we_PRP aim_VBP to_TO effectively_RB converting_VBG enzyme_JJ inhibitor_NN for_IN hypertension_NN ,_, heart_NN failure_NN and_CC diabetic_JJ nephropathy_NN in_IN Europe_NNP and_CC Japan_NNP ,_, while_IN manage_VB the_DT challenges_NNS of_IN the_DT increasing_VBG our_PRP$ strength_NN in_IN changing_VBG external_JJ environment_NN ,_, Key_NNP products_NNS :_: Gastrointestinal_JJ emerging_VBG markets_NNS ,_, such_JJ as_IN while_IN making_VBG the_DT most_JJS of_IN the_DT Losec_NNP Prilosec_NNP omeprazole_NN proton_NN pump_NN inhibitor_NN for_IN acid-related_JJ diseases_NNS China_NNP and_CC Mexico_NNP ._.
opportunities_NNS presented_VBN by_IN the_DT Nexium_NNP esomeprazole_NN magnesium_NN proton_NN pump_NN inhibitor_NN for_IN acid-related_JJ diseases_NNS Bruno_NNP Angelici_NNP ,_, growing_VBG demand_NN for_IN innovative_JJ Executive_NNP Vice-President_NNP ,_, medicines_NNS ._.
David_NNP Brennan_NNP ,_, Key_NNP products_NNS :_: Infection_NN 4_CD Merrem_NNP Meronem_NNP meropenem_NN ultra_NN broad_JJ Europe_NNP ,_, Japan_NNP ,_, Asia_NNP Pacific_NNP Executive_NNP Vice-President_NNP ,_, spectrum_NN injectable_JJ antibiotic_JJ for_IN serious_JJ and_CC ROW_NNP North_NNP America_NNP bacterial_JJ infection_NN Key_NNP products_NNS :_: Neuroscience_NNP We_PRP combine_VBP our_PRP$ global_JJ capabilities_NNS Toprol-XL_JJ and_CC Crestor_NNP ,_, with_IN combined_VBN Diprivan_NNP propofol_NN intravenous_JJ general_JJ anesthetic_NN for_IN induction_NN maintenance_NN of_IN anaesthesia_NN and_CC with_IN high_JJ quality_NN relationships_NNS in_IN our_PRP$ sales_NNS of_IN $_$ 5.7_CD billion_CD ,_, continue_VBP to_TO underpin_VB sedation_NN of_IN intensive_JJ care_NN patients_NNS local_JJ markets_NNS and_CC focus_VB on_IN responding_VBG our_PRP$ sales_NNS performance_NN in_IN this_DT highly_RB Naropin_JJ ropivacaine_NN local_JJ anesthetic_JJ quickly_RB and_CC effectively_RB to_TO our_PRP$ customers_NNS competitive_JJ market_NN ._.
for_IN surgical_JJ anaesthesia_NN and_CC acute_JJ pain_NN management_NN changing_VBG needs_NNS ._.
We_PRP sell_VBP mostly_RB through_IN Seroquel_NNP quetiapine_NN fumarate_NN atypical_JJ our_PRP$ own_JJ local_JJ marketing_NN companies_NNS In_IN Europe_NNP ,_, pharmaceutical_JJ cost_NN control_NN anti-psychotic_JJ for_IN schizophrenia_NN and_CC other_JJ and_CC our_PRP$ products_NNS are_VBP marketed_VBN mainly_RB pressure_NN continues_VBZ to_TO restrict_VB market_NN psychotic_JJ disorders_NNS Xylocaine_NNP lidocaine_NN local_JJ anesthetic_JJ for_IN use_NN to_TO physicians_NNS and_CC other_JJ healthcare_NN growth_NN ,_, which_WDT is_VBZ still_RB increasing_VBG but_CC at_IN a_DT in_IN surgery_NN and_CC dentistry_NN professionals_NNS ._.
Despite_IN this_DT background_NN ,_, our_PRP$ Zomig_NNP zolmitriptan_NN for_IN the_DT treatment_NN of_IN acute_JJ sales_NNS growth_NN outpaced_VBD the_DT overall_JJ market_NN ,_, migraine_NN with_IN or_CC without_IN aura_NN Our_PRP$ medicines_NNS are_VBP designed_VBN to_TO improve_VB with_IN a_DT strong_JJ performance_NN from_IN Crestor_NNP ,_, health_NN and_CC quality_NN of_IN life_NN ._.
They_PRP bring_VBP other_JJ Nexium_NNP ,_, Seroquel_NNP ,_, Arimidex_NNP and_CC Symbicort_NNP ._.
Key_NNP products_NNS :_: Oncology_NNP Arimidex_NNP anastrozole_NN aromatase_NN inhibitor_NN benefits_NNS too_RB ._.
We_PRP also_RB talk_VBP to_TO governments_NNS This_DT performance_NN ,_, coupled_VBN with_IN our_PRP$ for_IN breast_NN cancer_NN and_CC groups_NNS that_WDT buy_VBP healthcare_NN ,_, such_JJ as_IN investment_NN in_IN Central_NNP and_CC Eastern_NNP Europe_NNP ,_, Casodex_NNP bicalutamide_NN anti-androgen_NN managed_VBD care_NN organizations_NNS in_IN the_DT US_NNP ,_, provides_VBZ a_DT solid_JJ basis_NN for_IN future_JJ growth_NN in_IN for_IN prostate_NN cancer_NN Faslodex_NNP fulvestrant_JJ estrogen_NN receptor_NN about_IN the_DT economic_JJ as_RB well_RB as_IN the_DT the_DT region_NN ._.
Sales_NNS totalled_VBD $_$ 7.6_CD billion_CD in_IN 2004_CD antagonist_NN with_IN no_DT agonist_JJ effects_NNS for_IN breast_NN therapeutic_JJ advantages_NNS of_IN our_PRP$ range_NN ._.
and_CC AstraZeneca_NNP ranks_VBZ fifth_JJ in_IN Europe_NNP ._.
cancer_NN By_IN reducing_VBG the_DT incidence_NN of_IN disease_NN Iressa_NNP gefitinib_NN signal_NN transduction_NN inhibitor_NN for_IN non-small_JJ cell_NN lung_NN cancer_NN or_CC improving_VBG the_DT efficiency_NN of_IN treatment_NN ,_, In_IN Japan_NNP ,_, AstraZeneca_NNP was_VBD the_DT second_JJ Nolvadex_NNP tamoxifen_NN citrate_VB anti-oestrogen_JJ our_PRP$ medicines_NNS help_VBP to_TO relieve_VB the_DT growing_VBG fastest_JJS growing_VBG pharmaceutical_JJ company_NN for_IN breast_NN cancer_NN pressure_NN on_IN healthcare_NN systems_NNS and_CC in_IN 2004_CD ._.
A_DT strong_JJ performance_NN by_IN Zoladex_NNP goserelin_NN acetate_NN LHRH_NNP agonist_NN for_IN prostate_NN and_CC pre-menopausal_JJ breast_NN cancer_NN ,_, budgets_NNS ._.
Arimidex_NNP ,_, Casodex_NNP ,_, Zoladex_NNP and_CC Iressa_NNP ,_, certain_JJ benign_JJ gynaecological_JJ disorders_NNS and_CC and_CC good_JJ growth_NN for_IN Losec_NNP ,_, drove_VBD sales_NNS assisted_VBD reproduction_NN Success_NN in_IN key_JJ markets_NNS is_VBZ a_DT top_JJ priority_NN ._.
to_TO $_$ 1.4_CD billion_CD and_CC we_PRP now_RB rank_VBP 13th_JJ by_IN We_PRP aim_VBP to_TO build_VB on_IN our_PRP$ leading_VBG positions_NNS sales_NNS in_IN Japan_NNP ._.
Key_NNP products_NNS :_: Respiratory_JJ and_CC Inflammation_NNP in_IN major_JJ markets_NNS ,_, especially_RB the_DT US_NNP ,_, Accolate_NNP zafirlukast_NN oral_JJ leukotriene_NN receptor_NN antagonist_NN for_IN control_NN of_IN asthma_NN Japan_NNP and_CC Europe_NNP ,_, whilst_NN increasing_VBG our_PRP$ Overall_JJ sales_NNS in_IN Asia_NNP Pacific_NNP grew_VBD by_IN Oxis_NNP formoterol_NN inhaled_VBD fast_RB onset_NN long-acting_JJ strength_NN through_IN strategic_JJ investment_NN in_IN an_DT underlying_JJ rate_NN of_IN 18_CD %_NN to_TO $_$ 1.2_CD billion_CD bronchodilator_NN for_IN relief_NN of_IN asthma_NN symptoms_NNS the_DT small_JJ but_CC fast-growing_JJ markets_NNS of_IN the_DT and_CC the_DT region_NN represents_VBZ an_DT area_NN of_IN Pulmicort_NNP budesonide_NN inhaled_VBD anti-inflammatory_JJ for_IN asthma_NN control_NN future_JJ the_DT emerging_VBG economies_NNS ,_, high_JJ growth_NN potential_NN ._.
In_IN China_NNP ,_, we_PRP are_VBP Rhinocort_NNP budesonide_NN topical_JJ nasal_JJ such_JJ as_IN China_NNP and_CC Mexico_NNP ._.
now_RB the_DT largest_JJS multi-national_JJ prescription_NN anti-inflammatory_JJ for_IN control_NN of_IN rhinitis_NN drug_NN company_NN and_CC one_CD of_IN the_DT fastest_JJS Symbicort_NNP budesonide_NN formoterol_NN inhaled_VBD combination_NN of_IN anti-inflammatory_JJ and_CC fast_JJ onset_NN Our_PRP$ US_NNP sales_NNS of_IN $_$ 9.6_CD billion_CD in_IN 2004_CD reflect_VBP growing_VBG pharmaceutical_JJ companies_NNS ._.
long-acting_JJ bronchodilator_NN in_IN a_DT single_JJ inhaler_NN our_PRP$ commitment_NN to_TO driving_VBG growth_NN in_IN this_DT ,_, the_DT worlds_NNS largest_JJS pharmaceutical_JJ market_NN ._.
Elsewhere_RB ,_, good_JJ growth_NN in_IN Latin_NNP America_NNP 1_CD Licensed_VBN from_IN Takeda_NNP Chemical_NNP Industries_NNPS Ltd._NNP ._.
With_IN a_DT 5_CD %_NN market_NN share_NN ,_, AstraZeneca_NNP is_VBZ 27_CD %_NN and_CC a_DT $_$ 40_CD million_CD investment_NN in_IN new_JJ 2_CD Licensed_VBN from_IN Shionogi_NNP &_CC Co._NNP ._.
Ltd._NNP 3_CD the_DT fifth_JJ largest_JJS pharmaceutical_JJ company_NN ,_, manufacturing_VBG in_IN Egypt_NNP further_JJ strengthens_VBZ Licensed_VBN from_IN Merck_NNP &_CC Co._NNP ._.
Inc._NNP 4_CD Licensed_VBN from_IN Sumitomo_NNP Pharmaceuticals_NNP Co._NNP ._.
Ltd._NNP by_IN sales_NNS in_IN the_DT US_NNP ._.
Nexium_NNP ,_, Seroquel_NNP ,_, our_PRP$ platform_NN for_IN regional_JJ expansion_NN ._.
